Australian Patent Granted for NUZ-001
| Stock | NUZ.ASX (NUZ.ASX) |
|---|---|
| Release Time | 21 Oct 2025, 9:09 a.m. |
| Price Sensitive | Yes |
Australian Patent Granted for NUZ-001
- Australian patent granted covering NUZ-001 for the treatment of neurodegenerative diseases
- Complements the expedited US patent grant and provides unified runway through to May 2041
- Patent grant further strengthens global IP portfolio and ongoing work to support NUZ-001 commercialisation
Neurizon Therapeutics Limited (ASX: NUZ) has received notice from the Australian Patent Office of the grant of a new patent entitled 'Use of aminoacetonitrile compounds for the treatment of infection and disease' (patent number 2021272252). This method of use patent extends protection for Neurizon's lead drug candidate, NUZ-001, and related compounds across key therapeutic areas, including mTOR-pathway related diseases, such as ALS/MND, along with various other neurodegenerative diseases, in particular Alzheimer's disease, Huntington's disease and Parkinson's disease, as well as cancer and infectious diseases. This newly granted patent complements Neurizon's existing US Patent for NUZ-001 in neurodegenerative diseases and cancer and ensures unified intellectual property (IP) protection through to May 2041 across major global markets. The Company continues to advance a number of clinical development and commercialisation opportunities for NUZ-001, including entry into the HEALEY ALS Platform Trial expected later this year. Trial entry will be undertaken alongside a range of other initiatives, including ongoing partnerships, licensing and platform therapy development strategies across multiple disease areas.
The company remains well placed to unlock value from NUZ-001 through entry into the HEALEY ALS Platform Trial this quarter.
With the new Australian patent in place, Neurizon is ideally positioned to leverage Australia's exceptional early-phase clinical trial capabilities to accelerate development of NUZ-001. The company also remains fully committed to its pre-clinical program, showcasing NUZ-001's promise as a platform molecule with potential to address a range of neurodegenerative diseases that currently lack effective treatment options.